Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer

Authors

  • George Rodrigues
  • Xiaomei Yao
  • D. Andrew Loblaw
  • Michael Brundage
  • Joseph L. Chin

DOI:

https://doi.org/10.5489/cuaj.478

Keywords:

external beam radiation therapy, guideline recommendations, low-dose rate brachytherapy, prostate cancer, radical prostatectomy

Abstract

Objective: The Genitourinary Cancer Disease Site Group (GUDSG) and Cancer Care Ontario’s Program in Evidence-Based Care (PEBC) in Ontario, Canada developed a guideline on low-dose rate brachytherapy (LDR-BT) in patients with early-stage low-grade prostate cancer in 2001. The current updated guideline focuses on the research questions regarding the effect of LDR-BT alone, the effect of LDR-BT with external beam radiation therapy (EBRT) and the selection of an isotope.

Methods: This guideline was developed by using the methods of the Practice Guidelines Development Cycle and the core methodology was a systematic review. MEDLINE and EMBASE (from January 1996 to October 2011), the Cochrane Library, main guideline websites, and main annual meeting abstract websites specific for genitourinary diseases were searched. Internal and external reviews of the draft guideline were conducted.

Results: The draft guideline was developed according to a total of 10 systematic reviews and 55 full text articles that met the preplanned study selection criteria. The quality of evidence was low to moderate. The final report reflects integration of the feedback obtained through the internal review (two oncologists and a methodologist) and external review (five target reviewers and 48 professional consultation reviewers) process, with final approval given by the GU DSG and the PEBC.

Conclusion: The main recommendations are: (1) For patients with newly diagnosed low-risk or intermediate-risk prostate cancer who require or choose active treatment, LDR-BT alone is a treatment option as an alternative to EBRT alone or RP alone; and (2) I-125 and Pd-103 are each reasonable isotope options.

Downloads

Download data is not yet available.

Downloads

Published

2013-06-12

How to Cite

Rodrigues, G., Yao, X., Loblaw, D. A., Brundage, M., & Chin, J. L. (2013). Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. Canadian Urological Association Journal, 7(5-6), e411–6. https://doi.org/10.5489/cuaj.478

Issue

Section

Clinical Practice Guideline